Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.

Saki NakagawaMinoru MiyashitaIchiro MaedaAtsushi GodaHiroshi TadaMasakazu AmariYasuyuki KojimaKoichiro TsugawaYasuyo OhiYasuaki SagaraMiku SatoAkiko EbataNarumi Harada-ShojiTakashi SuzukiMakoto NakanishiTomohiko OhtaTakanori Ishida

Published in: Breast cancer research and treatment (2024)

Fbxo22 negativity significantly impacts on survival in BC patients with IDC and ILC, and the disadvantage was enhanced among ILC postmenopausal women or patients treated with SERMs. The findings suggest that different therapeutic strategies might be needed according to the different histopathological types when considering adjuvant endocrine therapy.

Keyphrases

postmenopausal women
bone mineral density
early stage
stem cells
smoking cessation